Starpharma announced that its proprietary VivaGel active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease).
Moderna has secured a funding commitment of up to $483m from the US Government agency Biomedical Advanced Research and Development Authority (BARDA) to advance the development of messenger RNA (mRNA) vaccine for novel coronavirus (SARS-CoV-2).
Novartis has collaborated with TScan Therapeutics for the discovery and development of T cell receptor (TCR) therapies to treat solid tumours.
British drugmaker GlaxoSmithKline (GSK) has joined forces with French pharma company Sanofi for the development of an adjuvanted vaccine for COVID-19 disease.
Alnylam Pharmaceuticals has entered into a $2bn strategic financing collaboration with Blackstone to advance the commercial potential of RNA interference (RNAi) therapeutics.
Enzychem Lifesciences announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering treating COVID-19 infections and symptoms using EC-18, the Company's lead compound.
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals have formed a development and commercialization collaboration on investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease (alpha-1 liver disease).
Gilead Sciences and Second Genome, a leader in microbiome science, announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease (IBD).
GlaxoSmithKline (GSK) has collaborated with Vir Biotechnology for the research and development of solutions for coronaviruses.
Shenogen has entered into an exclusive collaboration and licensing agreement with Shanghai BioArdis and BioArdis for the development and commercialization of BioArdis' novel FGFR4 (fibroblast growth factor receptor 4) kinase inhibitor, BIO-1262/SNG-203, either as monotherapy or combination therapy in Mainland China, Hong Kong, Macau and Taiwan.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.